시간 외 거래: 8.91

Aura Biosciences Inc (AURA)

Aura Biosciences Inc 주식(AURA)의 최신 뉴스

Aura Biosciences Inc (AURA)

Aura Biosciences Inc 주식(AURA)의 최신 뉴스

Where are the Opportunities in (AURA) - Stock Traders Daily

Ensign Peak Advisors Inc Sells 105,316 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat

Aura Biosciences names interim CFO as Julie Feder departs By Investing.com - Investing.com Australia

Aura Biosciences names interim CFO as Julie Feder departs - Investing.com

Wall Street SWOT: Aura Biosciences stock shows promise amid cancer treatment trials - Investing.com

Aura Biosciences Executives Transition and Compensation Update - TipRanks

Long Focus Capital Management LLC Has $7.99 Million Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat

Aura Energy (LON:AURA) Trading 11.1% Higher - MarketBeat

Bioxyne signs amendment with Aura Therapeutics to manufacture product volumes - Biotech Dispatch

Aurora Films to Go Public in Q4 2024 With Exclusive Token Issuance - EIN News

A Guide To The Risks Of Investing In Aurora Innovation Inc (AUR) - Knox Daily

Hancock Whitney Corp Makes New Investment in Acuity Brands, Inc. (NYSE:AYI) - Defense World

Financial Health Check: Examining Aurora Innovation Inc (AUR)’s Key Ratios - The Dwinnex

Should investors be concerned about Aurora Innovation Inc (AUR)? - US Post News

Bank of New York Mellon Corp Acquires 48,549 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World

Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream + - Seeking Alpha

Aurora Innovation (NASDAQ:AUR) Hits New 52-Week High at $5.31 - MarketBeat

Aura Biosciences (NASDAQ:AURA) Stock Rating Upgraded by Evercore ISI - MarketBeat

Aura Biosciences (NASDAQ:AURA) Raised to Strong-Buy at Evercore ISI - Defense World

$200M Cash, 8.8% Dividend Yield w/ 450K oz Gold Target | Aura Minerals with Rodrigo Barbosa - The Deep Dive

Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Up 5.7% in August - Defense World

aura Launches a One-Hour At-Home Health Check, Going Far Beyond Standard Blood Work - Business Wire

NCR's Realty Giant Gaurs Group Plans IPO, CMD Reveals Timeline, Projects and Other Details - News18

Aura Biosciences: Highly Derisked Late Stage Eye Cancer Company (NASDAQ:AURA) - Seeking Alpha

Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update - MarketBeat

Aura Biosciences (NASDAQ:AURA) Price Target Increased to $23.00 by Analysts at JMP Securities - MarketBeat

Aura Biosciences' (AURA) Buy Rating Reiterated at HC Wainwright - MarketBeat

Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study - Zacks Investment Research

Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study - Yahoo Finance

Aura Biosciences (NASDAQ:AURA) Shares Gap Up to $9.07 - MarketBeat

Aura Biosciences Touts Promising Data From Eye Cancer Candidate - Benzinga

Aura Biosciences Shares Jump in Premarket on Positive Phase 2 Ocular Cancer Treatment Results - MarketWatch

Lifesci Capital Comments on Aura Biosciences, Inc.'s Q3 2024 Earnings (NASDAQ:AURA) - MarketBeat

Aura reports promising results for ocular cancer therapy - Investing.com

Aura Biosciences’ Breakthrough in Choroidal Melanoma Treatment - TipRanks

Positive Phase II Bolsters Aura Bioscience’s Confidence in VDC-based Therapy for Ocular Melanomas - Genetic Engineering & Biotechnology News

Aura Biosciences Reports Positive Phase 2 End of Study - GlobeNewswire

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma - StockTitan

Aura Biosciences (NASDAQ:AURA) Lifted to Strong-Buy at Lifesci Capital - Defense World

Lifesci Capital Upgrades Aura Biosciences (NASDAQ:AURA) to Strong-Buy - MarketBeat

We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely - Simply Wall St

Levin Capital Strategies L.P. Purchases 216,266 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat

We're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate - Yahoo Finance

Aura Biosciences to Host a Urologic Oncology Investor Event - GlobeNewswire

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024 - StockTitan

A look into Aura Biosciences Inc (AURA)’s deeper side - SETE News

(AURA) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Aura Biosciences (NASDAQ:AURA) Receives Market Outperform Rating from JMP Securities - Defense World

Aura Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire

Aura Biosciences to Participate in Upcoming Investor Conferences - Marketscreener.com

Aura Biosciences to Participate in Upcoming Investor Conferences - StockTitan

Aura Biosciences' (AURA) Market Outperform Rating Reaffirmed at JMP Securities - MarketBeat

Short Interest in Aura Biosciences, Inc. (NASDAQ:AURA) Drops By 63.1% - MarketBeat

Aura Biosciences to Participate in Upcoming Investor Conferences - Yahoo Finance

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting - Yahoo Finance UK

Aura Biosciences Announces the Presentation of Phase 2 End - GlobeNewswire

Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting - StockTitan

Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting - Yahoo Finance

Novartis and Versant launch Borealis Biosciences with $150m - Pharmaceutical Technology

Calton & Associates Inc. Sells 4,149 Shares of Franklin BSP Realty Trust, Inc. (NYSE:FBRT) - Defense World

Values First Advisors Inc. Sells 9,167 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World

BioNTech (NASDAQ:BNTX) Stock Rating Reaffirmed by HC Wainwright - Defense World

iShares S&P 500 Growth ETF (NYSEARCA:IVW) Shares Bought by Raymond James & Associates - Defense World

The Carlyle Group Inc. (NASDAQ:CG) Short Interest Update - Defense World

AURA과 유사한 종목